These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Effect of carvedilol and nebivolol on oxidative stress-related parameters and endothelial function in patients with essential hypertension. Zepeda RJ; Castillo R; Rodrigo R; Prieto JC; Aramburu I; Brugere S; Galdames K; Noriega V; Miranda HF Basic Clin Pharmacol Toxicol; 2012 Nov; 111(5):309-16. PubMed ID: 22703478 [TBL] [Abstract][Full Text] [Related]
3. Vasodilating versus first-generation β-blockers for cardiovascular protection. Fares H; Lavie CJ; Ventura HO Postgrad Med; 2012 Mar; 124(2):7-15. PubMed ID: 22437211 [TBL] [Abstract][Full Text] [Related]
4. Realities of newer beta-blockers for the management of hypertension. Manrique C; Giles TD; Ferdinand KC; Sowers JR J Clin Hypertens (Greenwich); 2009 Jul; 11(7):369-75. PubMed ID: 19583633 [TBL] [Abstract][Full Text] [Related]
5. Pharmacologic considerations in the positioning of beta-blockers in antihypertensive therapy. Sica DA; Black HR Curr Hypertens Rep; 2008 Aug; 10(4):330-5. PubMed ID: 18625165 [TBL] [Abstract][Full Text] [Related]
6. The impact of third-generation beta-blocker antihypertensive treatment on endothelial function and the prothrombotic state: effects of smoking. Vyssoulis GP; Marinakis AG; Aznaouridis KA; Karpanou EA; Arapogianni AN; Cokkinos DV; Stefanadis CI Am J Hypertens; 2004 Jul; 17(7):582-9. PubMed ID: 15233977 [TBL] [Abstract][Full Text] [Related]
7. Beta-blockers in the treatment of hypertension: new data, new directions. Weber MA; Bakris GL; Giles TD; Messerli FH J Clin Hypertens (Greenwich); 2008 Mar; 10(3):234-8. PubMed ID: 18326967 [No Abstract] [Full Text] [Related]
8. Aortic elastic properties : effects of carvedilol versus nebivolol. Sayin MR; Aydin M; Dogan SM; Karabag T; Cetiner MA; Aktop Z Herz; 2013 May; 38(3):299-305. PubMed ID: 23263241 [TBL] [Abstract][Full Text] [Related]
9. The effects of newer beta-adrenoceptor antagonists on vascular function in cardiovascular disease. Wehland M; Grosse J; Simonsen U; Infanger M; Bauer J; Grimm D Curr Vasc Pharmacol; 2012 May; 10(3):378-90. PubMed ID: 22022769 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic dose of nebivolol, a nitric oxide-releasing beta-blocker, reduces atherosclerosis in cholesterol-fed rabbits. de Nigris F; Mancini FP; Balestrieri ML; Byrns R; Fiorito C; Williams-Ignarro S; Palagiano A; Crimi E; Ignarro LJ; Napoli C Nitric Oxide; 2008 Aug; 19(1):57-63. PubMed ID: 18435936 [TBL] [Abstract][Full Text] [Related]
11. Antihypertensive treatment with beta-blockers in the metabolic syndrome: a review. Carella AM; Antonucci G; Conte M; Di Pumpo M; Giancola A; Antonucci E Curr Diabetes Rev; 2010 Jul; 6(4):215-21. PubMed ID: 20459394 [TBL] [Abstract][Full Text] [Related]
12. Comparative long term effects of nebivolol and carvedilol in hypertensive heart failure patients. Marazzi G; Volterrani M; Caminiti G; Iaia L; Massaro R; Vitale C; Sposato B; Mercuro G; Rosano G J Card Fail; 2011 Sep; 17(9):703-9. PubMed ID: 21872138 [TBL] [Abstract][Full Text] [Related]
14. Beta-blockers for hypertension: are they going out of style? Che Q; Schreiber MJ; Rafey MA Cleve Clin J Med; 2009 Sep; 76(9):533-42. PubMed ID: 19726558 [TBL] [Abstract][Full Text] [Related]
15. β-blockers: a review of their pharmacological and physiological diversity in hypertension. Ripley TL; Saseen JJ Ann Pharmacother; 2014 Jun; 48(6):723-33. PubMed ID: 24687542 [TBL] [Abstract][Full Text] [Related]
16. An in-depth analysis of vasodilation in the management of hypertension: focus on adrenergic blockade. Bakris G J Cardiovasc Pharmacol; 2009 May; 53(5):379-87. PubMed ID: 19454898 [TBL] [Abstract][Full Text] [Related]
17. Nebivolol: third-generation beta-blockade. de Boer RA; Voors AA; van Veldhuisen DJ Expert Opin Pharmacother; 2007 Jul; 8(10):1539-50. PubMed ID: 17661735 [TBL] [Abstract][Full Text] [Related]
18. Effects of nebivolol versus carvedilol on left ventricular function in patients with chronic heart failure and reduced left ventricular systolic function. Lombardo RM; Reina C; Abrignani MG; Rizzo PA; Braschi A; De Castro S Am J Cardiovasc Drugs; 2006; 6(4):259-63. PubMed ID: 16913827 [TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of effect of beta-blocker therapy on mortality in patients with New York Heart Association class IV chronic congestive heart failure. Whorlow SL; Krum H Am J Cardiol; 2000 Oct; 86(8):886-9. PubMed ID: 11024409 [No Abstract] [Full Text] [Related] [Next] [New Search]